Crohn's Disease
Key Terms
- IBD
- Inflammatory Bowel Diease
- IBD Flare
- previoulsy sx free but now w/ sx
- Primary Nonresponse
- no response to pharmacotherpy
- Secondary Nonresponse
- d/t either low lvl of therapy or antibody generation against pharm agent
Epidem
Etiology
- Initial Insult
- Disease Flare
- Antibody generation against pharmacotherapy
- Infection
- Medication non compliance
- Obesity, sleep disturbance, stress
- Cigarette Smoking
Patho
- Explain the functional changes associated with the condition here.
HPI
- Include details about the patient's symptoms and history here.
Physical Exam
- Describe key findings from the physical examination here.
Diagnostics
- General Monitoring
- If sx free, monitor in 3-6 months
- If sx, immediately assess for active inflammation/infection
- Low drug levels
- development of antibodies to therapy
- Screenings
- Bone mineral density -> DEXA
- Melanoma -> Dermatology
- Cervical Cancer -> PAP Smear (annually w/ immunosuppressives)
- Anxiety / Depression -> PHQ-9
- Colorectal Cancer -> Colonoscopy
- Anemia -> CBC, Iron, ferritin, folate, B12,
- Nutrition -> albumin
- IBD Flare
- imaging is indicated because labs do not differentiate b/w infection and inflammation
- gold standard is colonoscopy
- colonoscopy > MRE > abdominal CT
- C. diff testing
- if recent travel to endemic areas, parasitic testing
- Fecal Calprotectin
- correlation b/w small and large intestinal inflammation and endoscopic disease activity
- more sensitive than ESR/CRP
- does not differentiate b/w small and large intestinal inflammation
- does not differentiate b/w inflammation and infection processes
- Asymtomatic pt w/ elevated lvl means sx recurrence w/in 3 months
- Nrml lvl means remission of sx for about 3 months
- CRP - C-reactive Protein
- ESR
- Ileocolonsocopy
- Gold Standar in assessing disease activity
Tx
- Lifestyle Modification
- Smoking Cessation
- Weight loss if overweight
- Preventative
- Vaccines - recommendations are different for this pt population
- Pneumococcal Vaccine
- COVID-19 Vaccine
- High Dose Influenza Vaccine(not live vaccine d/t immunosuppressives)
- Herpes Zoster
- Hep A, Hep B
- Tdap
- HPV
- Meningococal
- MMR / Varicella (not while on immunosuppressives
- Immunosuppressive Therapy
- TNF Agents
- Infliximab
- If antidrug antibodies, switch to different agent rather than increase dose
- Adalimumab
- Vedolizumab
- Ustekinumab
- if primary non-response to anti-TNF
- Recent FDA approvals: Risankizumab and Upadacitinib
- Surgical
- involve surgery early in the care of Crohn's Disease
Referrals
- Dermatology
- risk of developing melanoma w/ anti-TNF agents
- risk of developing non-melanoma squamous cell cancer
- thus need individualized plan for ongoing skin cancer surveilance
- Surgery
References